The longitudinal impact of bars with rounded ends

Not availabl

Exposing the human nude phenotype [4]

Peer reviewedSubmitted Versio

Hyperon-hyperon interactions and properties of neutron matter

We present results from Brueckner-Hartree-Fock calculatons for beta stable neutron star matter with nucleonic and hyperonic degress degrees of freedom, employing the most recent parametrizations of the baryon-baryon interaction of the Nijmegen group. It is found that the only strange baryons emergin in beta stable matter up to total barionic densities of 1.2 fm^-3 are $\Sigma^-$ and $\Lambda$. The corresponding equations of state are then used to compute properties of neutron stars such as masses and radii.Comment: 27 pages, LateX, includes 8 PostScript figures, (submitted to PRC

Warm strange hadronic matter in an effective model with a weak Y-Y interaction

An effective model is used to study the equation of state of warm strange hadronic matter with nucleons, Lambda-hyperons, Xi-hyperons, sigmastar and phi. In the calculation, a newest weak Y-Y interaction deduced from the recent observation of a He double hypernucleus is adopted. Employing this effective model, the results with strong Y-Y interaction and weak Y-Y interaction are compared.Comment: 9 pages, 9 figure

Neutron Star Constraints on the H Dibaryon

We study the influence of a possible H dibaryon condensate on the equation of state and the overall properties of neutron stars whose population otherwise contains nucleons and hyperons. In particular, we are interested in the question of whether neutron stars and their masses can be used to say anything about the existence and properties of the H dibaryon. We find that the equation of state is softened by the appearance of a dibaryon condensate and can result in a mass plateau for neutron stars. If the limiting neutron star mass is about that of the Hulse-Taylor pulsar a condensate of H dibaryons of vacuum mass 2.2 GeV and a moderately attractive potential in the medium could not be ruled out. On the other hand, if the medium potential were even moderately repulsive, the H, would not likely exist in neutron stars. If neutron stars of about 1.6 solar mass were known to exist, attractive medium effects for the H could be ruled out. Certain ranges of dibaryon mass and potential can be excluded by the mass of the Hulse-Taylor pulsar which we illustrate graphically.Comment: Revised by the addition of a figure showing the region of dibaryon mass and potential excluded by the Hulse-Taylor pulsar. 18 pages, 11 figures, latex (submitted to Phys. Rev. C

The Synthesis Telescope at the Dominion Radio Astrophysical Observatory

We describe an aperture synthesis radio telescope optimized for studies of the Galactic interstellar medium (ISM), providing the ability to image extended structures with high angular resolution over wide fields. The telescope produces images of atomic hydrogen emission using the 21-cm HI spectral line, and, simultaneously, continuum emission in two bands centred at 1420 MHz and 408 MHz, including linearly polarized emission at 1420 MHz, with synthesized beams of 1 degree and 3.4 degrees at the respective frequencies.Comment: Accepted for publication by Astronomy and Astrophysics, Supplement Serie

Dihyperon in Chiral Colour Dielectric Model

The mass of dihyperon with spin, parity $J^{\pi}=0^{+}$ and isospin $I = 0$ is calculated in the framework of Chiral colour dielectric model. The wave function of the dihyperon is expressed as a product of two colour-singlet baryon clusters. Thus the quark wave functions within the cluster are antisymmetric. Appropriate operators are then used to antisymmetrize inter-cluster quark wave functions. The radial part of the quark wavefunctions are obtained by solving the the quark and dielectric field equations of motion obtained in the Colour dielectric model. The mass of the dihyperon is computed by including the colour magnetic energy as well as the energy due to meson interaction. The recoil correction to the dihyperon mass is incorporated by Peierls-Yoccoz technique. We find that the mass of the dihyperon is smaller than the $\Lambda-\Lambda$ threshold by over 100 MeV. The implications of our results on the present day relativistic heavy ion experiments is discussed.Comment: LaTeX, 13 page

Nuclei, Superheavy Nuclei and Hypermatter in a chiral SU(3)-Modell

A model based on chiral SU(3)-symmetry in nonlinear realisation is used for the investigation of nuclei, superheavy nuclei, hypernuclei and multistrange nuclear objects (so called MEMOs). The model works very well in the case of nuclei and hypernuclei with one Lambda-particle and rules out MEMOs. Basic observables which are known for nuclei and hypernuclei are reproduced satisfactorily. The model predicts Z=120 and N=172, 184 and 198 as the next shell closures in the region of superheavy nuclei. The calculations have been performed in self-consistent relativistic mean field approximation assuming spherical symmetry. The parameters were adapted to known nuclei.Comment: 19 pages, 11 figure

Detectability of Strange Matter in Heavy Ion Experiments

We discuss the properties of two distinct forms of hypothetical strange matter, small lumps of strange quark matter (strangelets) and of hyperon matter (metastable exotic multihypernuclear objects: MEMOs), with special emphasis on their relevance for present and future heavy ion experiments. The masses of small strangelets up to A = 40 are calculated using the MIT bag model with shell mode filling for various bag parameters. The strangelets are checked for possible strong and weak hadronic decays, also taking into account multiple hadron decays. It is found that strangelets which are stable against strong decay are most likely highly negative charged, contrary to previous findings. Strangelets can be stable against weak hadronic decay but their masses and charges are still rather high. This has serious impact on the present high sensitivity searches in heavy ion experiments at the AGS and CERN facilities. On the other hand, highly charged MEMOs are predicted on the basis of an extended relativistic mean-field model. Those objects could be detected in future experiments searching for short-lived, rare composites. It is demonstrated that future experiments can be sensitive to a much wider variety of strangelets.Comment: 26 pages, 5 figures, uses RevTeX and epsf.st

Pharmacokinetics of intramuscular tranexamic acid in bleeding trauma patients: a clinical trial.

BACKGROUND: Intravenous tranexamic acid (TXA) reduces bleeding deaths after injury and childbirth. It is most effective when given early. In many countries, pre-hospital care is provided by people who cannot give i.v. injections. We examined the pharmacokinetics of intramuscular TXA in bleeding trauma patients. METHODS: We conducted an open-label pharmacokinetic study in two UK hospitals. Thirty bleeding trauma patients received a loading dose of TXA 1 g i.v., as per guidelines. The second TXA dose was given as two 5 ml (0·5 g each) i.m. injections. We collected blood at intervals and monitored injection sites. We measured TXA concentrations using liquid chromatography coupled to mass spectrometry. We assessed the concentration time course using non-linear mixed-effect models with age, sex, ethnicity, body weight, type of injury, signs of shock, and glomerular filtration rate as possible covariates. RESULTS: Intramuscular TXA was well tolerated with only mild injection site reactions. A two-compartment open model with first-order absorption and elimination best described the data. For a 70-kg patient, aged 44 yr without signs of shock, the population estimates were 1.94 h-1 for i.m. absorption constant, 0.77 for i.m. bioavailability, 7.1 L h-1 for elimination clearance, 11.7 L h-1 for inter-compartmental clearance, 16.1 L volume of central compartment, and 9.4 L volume of the peripheral compartment. The time to reach therapeutic concentrations (5 or 10 mg L-1) after a single intramuscular TXA 1 g injection are 4 or 11 min, with the time above these concentrations being 10 or 5.6 h, respectively. CONCLUSIONS: In bleeding trauma patients, intramuscular TXA is well tolerated and rapidly absorbed. CLINICAL TRIAL REGISTRATION: 2019-000898-23 (EudraCT); NCT03875937 (ClinicalTrials.gov)